Crown Bio adds services at newly expanded oncology center

By Melissa Fassbender contact

- Last updated on GMT

The immuno-oncology market is expected to see annual revenues of up to $40bn by 2020. (Image: iStock/TanawatPontchour)
The immuno-oncology market is expected to see annual revenues of up to $40bn by 2020. (Image: iStock/TanawatPontchour)

Related tags: Cell biology

Crown Bioscience has expanded its oncology services with new models, cell lines, and assays at its San Diego-based Center of Excellence for Oncology.

The Center of Excellence was launched​ in July, in order to support increasing demand for oncology research studies. As Outsourcing-Pharma.com reported​ at the time, the USDA-certified facility features multiple holding rooms and dedicated procedure and formulation spaces.

The new services introduce various platforms for immuno-oncology program evaluation and new technologies for traditional oncology agents.

Globally, CrownBio has seen an increase in demand​ for its immuno-oncology services. As such, the company has made several previous additions to its offerings to include a collection of validated models and services for vivo pharmacodynamics and efficacy studies, including multi-color flow cytometry, immunohistochemistry, and multiplex ELISA.

According to the company, the newly expanded site will be able to provide avatar clinical trials (HuTrials™) with Humanized NSG™ xenografts.

The company has also developed new PDX derived cell lines to supplement its PrimePanel™ collection and has developed expanded 3D-tumor growth assays (3D-TGA) for most indications.

Related news

Show more

Related products

show more

Related suppliers

Follow us

Products

View more

Webinars